Waters and BD’s Biosciences & Diagnostic Solutions to Combine
Waters and BD are merging BD's Biosciences & Diagnostic Solutions unit with Waters in a $17.5 billion Reverse Morris Trust transaction.
Waters and BD are merging BD's Biosciences & Diagnostic Solutions unit with Waters in a $17.5 billion Reverse Morris Trust transaction.
The ADLM has urged HHS to reinstate the CLIAC, warning that its elimination endangers test quality and patient care.
Xifin has added two major payors to its Payor Rate Transparency Monitor. Labs will now have even more data to help with reimbursements.
COLA Inc. is rebranding as the Commission on Laboratory Accreditation (COLA) to better reflect its mission promoting laboratory excellence.
Xifin’s CEO sees a window of opportunity for lawmakers to modify the Final Rule on LDTs that will be a win-win for the industry and patients.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
NeoGenomics, Inc. has acquired Pathliine, expanding its oncology testing services and accelerating growth in other testing.
Join Tosoh Bioscience and Dr. Giuliana Puccini Santamaria for a deep dive into fertility markers and their role in diagnosing and managing infertility. This webinar explores key indicators like ovarian function, polycystic ovarian syndrome, and the importance of fast, accurate immunoassay results in fertility treatment. Ideal for clinicians seeking actionable insights in reproductive health.